Welcome to the Hope Bio Blog

By Jan Shultis, Ph.D. Earlier this year, a peer-reviewed piece on an FDA-authorized clinical trial in Parkinson’s Disease was published by Wiley. Currently screening is underway for another Parkinson’s Disease trial, the seventh using Hope Bio’s cells to date, while detailed analysis continues on a completed Phase II trial that announced positive topline results. As we head into the fourth quarter of 2026, let’s take a look at what the Wiley piece says in plain language, wher

By Jan Shultis, Ph.D. Welcome to Hope Bio’s newly renovated home (keep reading for construction updates and pictures)! In the third and final part of our “location, location, location” series, let’s talk about why Hope Bio is thriving in Sugar Land, Texas. New here? Click here to read part one, about how headquartering in the United States affects your access to cellular therapeutics, with emphasis on manufacturing and research standards. Click here for part two, to dive in

By Jan Shultis, Ph.D. In part one of a three-part series about what Hope Biosciences’ location means to you, we discussed how the decision to headquarter in the United States (U.S.) affects manufacturing standards at Hope Biosciences and patient access to cellular therapeutics. Click here to read the piece, if you missed it – in making your healthcare decisions, it is useful to how and why industry standards such as Good Manufacturing Practice (GMP) shape your interaction wit